Actualités Dare Bioscience Inc - DARE | Actions NASDAQ

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14APROXY STATEMENT PURSUANT TO SECTION 14(A) OF THESECURITIES...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14APROXY STATEMENT PURSUANT TO SECTION 14(A) OF THESECURITIES...

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in...

David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms due to...

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Current Report Filing (8-k)

0001401914 false Dare Bioscience, Inc. 0001401914 2023-03-30 2023-03-30...

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement...

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Current Report Filing (8-k)

0001401914 false Dare Bioscience, Inc. 0001401914 2023-03-13 2023-03-13...

Daré Bioscience to Present at the 35th Annual Roth Conference

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Dare Bioscience Inc (DARE)

Outils de qualité professionnelle, pour des investisseurs individuels.

DARE Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

Current Report Filing (8-k)

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

Current Report Filing (8-k)

Daré Bioscience to Present at the 35th Annual Roth Conference

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

Current Report Filing (8-k)

Daré Bioscience to Participate in Three February Conferences

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Dare Bioscience Inc (DARE) Actualités

Dare Bioscience Inc (DARE)

Outils de qualité professionnelle, pour des investisseurs individuels.

DARE Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

Current Report Filing (8-k)

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

Current Report Filing (8-k)

Daré Bioscience to Present at the 35th Annual Roth Conference

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

Current Report Filing (8-k)

Daré Bioscience to Participate in Three February Conferences

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application